(Q50906224)

English

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

scientific article published on 13 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. (English)

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

4

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Winfried B. Graninger

0 references

1 reference

ORCID Public Data File 2021

Arthur Kavanaugh

2

object named as

Arthur Kavanaugh

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

author name string

Alice B Gottlieb

3

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Proton Rahman

5

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Christopher Ritchlin

6

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Carrie Brodmerkel

7

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Shu Li

8

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Yuhua Wang

9

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Alan M Mendelsohn

10

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Mittie K Doyle

11

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

PSUMMIT 1 Study Group

12

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

language of work or name

0 references

publication date

13 June 2013

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

382

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

9894

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

780-789

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Prevalence of joint disease in patients with psoriasis: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of enthesitis in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-12p35 promotes antibody-induced joint inflammation by activating NKT cells and suppressing TGF-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960594-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)60594-2

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23769296

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50906224&oldid=1935719156"